vTv Therapeutics (VTVT) EBITDA Margin (2014 - 2026)

vTv Therapeutics has disclosed EBITDA Margin across 11 years of filings, most recently posting 63.15% for Q1 2026.

• EBITDA Margin for Q1 2026 came in at 63.15%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was 8.26% (up 14737998.0% YoY), and the FY2024 annual result was 2377.58%, changed N/A from the prior year.
• EBITDA Margin came in at 63.15% for Q1 2026 at vTv Therapeutics, up from 28776.47% in the prior quarter.
• In the past five years, EBITDA Margin ranged from a high of 63.15% in Q1 2026 to a low of 70477.78% in Q4 2022.
• The 3-year median for EBITDA Margin is 14669.59% (2024), against an average of 24137.05%.
• Peak annual rise in EBITDA Margin reached 5295556 bps in 2022, while the deepest fall reached 10959 bps in 2022.
• vTv Therapeutics' EBITDA Margin stood at 70477.78% in 2022, then soared by 59 bps to 28776.47% in 2024, then soared by 100 bps to 63.15% in 2026.
• The last three EBITDA Margin figures came in at 63.15% (Q1 2026), 28776.47% (Q4 2024), and 562.7% (Q1 2024), per Business Quant data.